Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
The Phage raises ¥570 million in Series A funding led by Itochu Technology Ventures to develop AI blood glucose prediction technology. The company also forms strategic alliance with Tokio Marine Holdings.
Amount Raised
¥570 Million
Round Type
Series A
Investors
Description
The Phage, a developer of AI-powered continuous glucose foundation models (CGFM), announced it has raised ¥570 million through a Series A 1st round equity allocation and loans. The round was led by Itochu Technology Ventures, with new investors Tokio Marine & Nichido Fire Insurance and Fukui Capital Partners, alongside returning investors Genesia Ventures and Vision Incubate. The Shoko Chukin Bank provided loan financing. Additionally, The Phage established a capital and business alliance with Tokio Marine Holdings to commercialize healthcare solutions for lifestyle-related disease prevention.
Fundz sees it the moment The Phage raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansThe Phage raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.